1-isopentyl-3-phenylurea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-isopentyl-3-phenylurea
• 英文别名: N-isopentyl-N'-phenyl-urea；N-Isopentyl-N'-phenyl-harnstoff；1-(3-Methylbutyl)-3-phenylurea
• 化学式: C₁₂H₁₈N₂O
• mdl: MFCD00475005
• 分子量: 206.288
• InChiKey: NLKIRMSPMYBHEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异戊醇 、 苯基脲 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 sodium hydroxide 作用下， 反应 12.0h， 以70%的产率得到1-isopentyl-3-phenylurea
  参考文献：
  名称：

  一种合成N，N’-二取代基脲的方法

  摘要：

  本发明公开了一种合成N,N’-二取代基脲的新方法，在反应容器中，加入N-取代基脲、金属铱、铑或钌络合物催化剂、碱、化合物醇和溶剂（或不加溶剂）；反应混合物在90-130oC下反应数小时后，冷却到室温；旋转蒸发除去溶剂，然后通过柱分离，得到目标化合物。同现有技术相比，本发明从商品化或容易合成的N-取代基脲出发，通过和醇发生区域选择性烷基化反应，得到的N,N’-二取代基脲，反应展现出三个显著的优点：1）使用近于无毒的醇为烷基化试剂；2）反应只生成水为副产物，无环境危害；3）反应原子经济性高；因此，该反应符合绿色化学的要求，具有广阔的发展前景。

  公开号：

  CN103664704B

文献信息

• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。
• GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20100056530A1

  公开（公告）日：2010-03-04

  Provided are compounds of Formula I wherein R 1 , R 2 , Y, Z and G are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了式I化合物，其中R1、R2、Y、Z和G的定义如本文所述，这些化合物对于治疗和/或预防由胰岛素敏感性激酶活性不足引起的疾病（如糖尿病）是有用的。还提供了治疗或预防由胰岛素敏感性激酶活性不足或可以通过激活胰岛素敏感性激酶来治疗的疾病和疾病的方法。
• RENIN INHIBITORS
  申请人：Kwok Lily

  公开号：US20100105665A1

  公开（公告）日：2010-04-29

  Compounds, pharmaceutical compositions, kits, article of manufacture, methods of using, and method of preparing of compounds having the formula of: wherein the variables are as defined herein.

  化合物、药物组合物、试剂盒、制造物品、使用方法和制备方法，具有以下式子的化合物：其中变量的定义如下。
• Curtius, Journal fur praktische Chemie (Leipzig 1954), 1930, vol. <2> 125, p. 152,184
  作者：Curtius

  DOI：——

  日期：——
• NOVEL COMPOUNDS AND USES
  申请人：The University of Queensland

  公开号：US20200207780A1

  公开（公告）日：2020-07-02

  The present invention relates to compounds of formula (I): wherein Q is O or S; R 1 is a cyclic group substituted with at least one group X, wherein R 1 may optionally be further substituted; X is any group comprising a carbonyl group; and R 2 is a cyclic group substituted at the α-position, wherein R 2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP 3 inhibition and the stimulation of insulin secretion.